

PTO/SB/05 (12/97)
Approved for use through 09/30/00. OMB 061-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type	a plus sign (+) inside this box → +							
	UTILITY	Attny Dock			75 0			
		ed Inventor or Application Identifier		- H				
, (Only	TRANSMITTAL for new nonprovisional applications under 37 CFR 1	Ebner et			<u> </u>			
(0,		Date	July 15, 1998		<u> </u>			
See MPEP char	APPLICATION ELEMEN pter 600 concerning utility patent application contents			ssistant Commissioner	for Patents			
	, and a control of the control of th	**		ox Patent Application	40			
1 M F0	e Transmittal Form			Vashington, D.C. 20231				
	ecification [total pgs.	631		ne Computer Program				
	eferred arrangement set forth	-		7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)				
				a. Computer Readable Copy				
 Descriptive title of the Invention Cross References to Related Applications 			a. M Computer	Readable Copy				
	tement Regarding Fed Sponso		h M Paper Co	one (identical to com				
	ference to Microfiche Appendi		b. 🗵 Paper Copy (identical to computer copy)					
- Background of the Invention			o ⊠ Statemer	c. Statement verifying identity of above copies				
	ief Summary of the Invention		C. Z Statemen	c. 23 Statement verifying identity of above copies				
	ief Description of the Drawing	as (if filed)	Accompanying	~ Application Ports				
		JS (II IIIGG)	Accompanying Application Parts 8. Assignment Papers (cover and document(s))					
	tailed Description ıim(s)							
	estract of the Disclosure		9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attny 10. ☐ English Translation Document					
3. a. Drav		ate 3	10. L. English Translation Document					
	quence Listing Total page				•			
₩. -	,doilee Lieg	,,,	11. Informat	tion Disclosure Stat	ement/PTO-1449			
4. XOat	th or Declaration Total pag	ies 2	Copies of IDS Citations					
	· •		12. Preliminary Amendment					
b.	Copy from a prior application			13. Return Receipt Postcard (MPEP 503)				
	(for con/div with Box 17 con		(should be specifically itemized)					
i.	Deletion of Inventors	•	14. Small Entity Statement(s)					
(signed statement attached deleting			Statement filed in prior application, status					
	inventor(s) named in prior a		still proper and desired					
	poration by Reference (with E		15. Certified copy of priority document(s)					
The entire	e disclosure of the prior application	on, from	16. Other:					
	opy of the oath or declaration is							
	4b, is considered as being part of the accompanying application							
	corporated by reference therein.							
17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:								
and supply the requirementalism.								
☐ Contin	nuation Divisional	Continuation	on-in-Part (CIP)	of prior application I	۱۰ ا			
			ESPONDENCE AD					
Custo	mer Number or Bar Code Labe			pondence address be	low			
Name								
Human Genome Sciences, Inc.			a de la compa					
Address								
City		tate MD	Zip (Code 20850				
Country	US Telephone		301-309-8504		309-8439			
_								
		1		7/15/9	10			
	1.000		Reg. No. 36,373	T/13/1	8			
	Signature			Data				





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ebner et al.

Application Serial No.: Not assigned

Art Unit: Not assigned

Filed: Concurrently herewith

Examiner: Not assigned

For:

Interleukin-20

Attorney Docket No.: PF399

STATEMENT UNDER 37 C.F.R. 1.821(f)

Assistant Commissioner For Patents Washington, D.C. 20231

Sir:

Applicants hereby certify that the hard copy of the sequence listing being filed concurrently herewith and the enclosed computer-readable form of such sequence listing are identical.

Respectfully submitted,

Dated: 7/5/58

A. Anders Brookes

Reg. No. 36,373

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, Maryland 20850 Telephone: 301-309-8504

Enclosure AAB/JK/mbp



American Type Culture Collection

12301 Parklawn Drive ● Rockville, MD 20852 USA ● Telephone: 301-231-5519 or 231-5532 ● FAX: 301-816-4366

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2



To: (Name and Address of Depositor or Attorney)

Human Genome Sciences, Inc. Attn: Robert H. Benson 9410 Key West Avenue Rockville, MD 20850

Deposited on Behalf of: Human Genome Sciences, Inc.

Identification Reference by Depositor:

ATCC Designation

DNA Plasmid HTS6530 (Ref. Docket PF399)

209232

The deposit was accompanied by: ___ a scientific description _ a proposed taxonomic description indicated above.

The deposit was received August 29, 1997 by this International Depository Authority and has been accepted.

AT YOUR REQUEST: X We will inform you of requests for the strain for 30 years.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strain.

If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested September 26, 1997. On that date, the culture was viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Barbara M. Hailey, Administrator, Patent Depository

Date: September 26, 1997



American Type Culture Collection

12301 Parklawn Drive ● Rockville, MD 20852 USA ● Telephone: 301-231-5519 or 231-5532 ● FAX: 301-816-4366

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3 AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

je542 U.S. 09/1158

To: (Name and Address of Depositor or Attorney)

Human Genome Sciences, Inc. Attn: Robert H. Benson 9410 Key West Avenue Rockville, MD 20850 RECENTE

HGS PATENT LLP I

Deposited on Behalf of: Human Genome Sciences, Inc.

Identification Reference by Depositor:

DNA Plasmid HSIEH63 (Ref. PF297) DNA Plasmid PS037 (Ref. PS-037) DNA Plasmid PS038 (Ref PS-038) **ATCC Designation**

209137 ⁷ 209138 209139

The deposits were accompanied by: __ a scientific description _a proposed taxonomic description indicated above.

The deposits were received July 3, 1997 by this International Depository Authority and have been accepted.

AT YOUR REQUEST:

We will inform you of requests for the strains for 30 years.

The strains will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strains, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strains.

If the cultures should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace them with living cultures of the same.

The strains will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the cultures cited above was tested July 10, 1997. On that date, the cultures were viable.

International Depository Authority: American Type Culture Collection, Rockville, Md. 20852 USA

Signature of person having authority to represent ATCC:

Barbara M. Hailey, Administrator, Patent Depository

Date: July 10, 1997

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Ebner et al.

Application Serial No.: Not assigned

Filed: Concurrently herewith

For:

Interleukin-20

Attorney Docket No.: PF399

PATENT APPLICATION FEE VALUE

Assistant Commissioner for Patents **Box PATENT APPLICATION** Washington, D.C. 20231

Sir:

The filing fee the subject application being filed concurrently herewith has been calculated as follows:

TYPE	NO. FILE	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	22	-20	2	\$22.00 each	\$44.00
Independent	7	-3	4	\$82.00 each	\$ 328.00
Minimum Fee					\$ 790.00
			Multiple Depoif applicable	, "	
	\$ 1,162.00				

Priority of Provisional Application Serial No. 60/052,870, filed on July 16, 1997 and Application Serial No: 60/060,140 filed September 26, 1997, are hereby claimed under 35 U.S.C. §119(e).

Please charge the required fee to Deposit Account No. 08-3425. In addition, the Commissioner is hereby authorized to charge payment for any additional filing fees required under 37 C.F.R. 1.16 or credit any overpayment to Deposit Account No. 08-3425. A duplicate of this paper is attached.

Respectfully submitted,

7/15/58 Date

A. Anders Brookes

(Reg. No. 36,373)

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 (301) 850-4985 (telephone)

Enclosure

AAB/JK/mbp